The End of Trial and Error.
End-to-end drug effect simulation. From molecule to market, predicted before a single patient enrolls.
Over 90% of drugs entering clinical trials fail to reach approval. Most late-stage failures are traceable to problems that were present before the trial began: the wrong dose, the wrong patient population, the wrong endpoint. None of them required a failed trial to discover. They required a better model.
The Platform
OVIVO connects the full biological chain — from a patient's genetics through drug absorption, metabolism, receptor engagement, pathway modulation, and disease progression — and translates it into the clinical endpoints that trials actually measure. Every output is traceable to its source. Every prediction carries an honest uncertainty bound.
Drug Effect Simulations
From pharmacogenomics to benefit-risk, the full chain connected. No isolated modules. No black-box outputs.
Explore simulations →
Clinical Trial Predictions
Simulate your trial before you run it. Optimize protocol, predict outcomes, identify failure modes — before any patient enrolls.
Explore trials →
De Novo Drug Discovery
Start with what the disease needs. Identify targets from biological gaps, generate candidates, validate them through the full simulation chain.
Explore discovery →
Precision Medicine
The same platform, run at the level of one patient — their genetics, their disease, their current treatment — to surface what the data shows.
Explore precision medicine →Validated. Independently verifiable. And growing.
A prediction that cannot be traced back to its inputs is not a prediction. It is an opinion. Every number OVIVO produces has a chain of custody — the data source, the confidence level, the calculation method. Mechanistic. Traceable. Honest.
For Pharma, Biotech and CROs
Co-development partnerships for trial design, pipeline de-risking, competitive analysis, drug repurposing, and combination strategy. We're actively looking for partners.
develop@ovivolabs.comFor Investors
A demonstrable, independently verifiable prediction record across drug development's most expensive failure points. Growing validation library. Clear trajectory.
invest@ovivolabs.comFor Patients and Clinical Teams
For complex, rare, or treatment-resistant cases where the standard pathway offers limited answers. This is research data, not clinical advice. Clinical decisions belong with your team.
media@ovivolabs.com